Short answer
PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal quarter ended September 30, 2026 results announced.
PULSE BIOSCIENCES, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter ended September 30, 2026 results announced
- Financial and operational details provided in Exhibit 99.1
- Results announcement gives investors an update on quarterly performance and operating progress
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $0.4M versus $0.1M, but controlled Vybrance launch continues through Q4 2027
- NANOPULSE-AF enrollment complete: 169 evaluable patients across 15 sites, three months ahead of plan
- Cash, equivalents and securities $189.2M, boosted by $95.8M ATM proceeds and over $150M raised since May
- GAAP net loss widened to $23.1M from $19.4M as clinical and employee costs increased
- Key catalysts: 12-month EU data in Q1 2027, persistent AF IDE submission in Q4 2026, anticipated CE Mark approval in Q4 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PULSE BIOSCIENCES, INC. 8-K filings
Get the next PLSE 8-K as it lands
Follow PLSE for push alerts, or ask the research agent what this filing means.